Johnson Financial Group Inc. Trims Stock Position in Pfizer Inc. (NYSE:PFE)

Johnson Financial Group Inc. cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 43.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 79,371 shares of the biopharmaceutical company’s stock after selling 61,027 shares during the quarter. Johnson Financial Group Inc.’s holdings in Pfizer were worth $2,285,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. VisionPoint Advisory Group LLC raised its holdings in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the period. GoalVest Advisory LLC raised its holdings in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the period. Tennessee Valley Asset Management Partners purchased a new position in shares of Pfizer in the 4th quarter worth about $36,000. DiNuzzo Private Wealth Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at about $37,000. Finally, Life Planning Partners Inc acquired a new stake in shares of Pfizer in the fourth quarter valued at about $39,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.19 during mid-day trading on Friday, hitting $28.88. The company had a trading volume of 22,578,167 shares, compared to its average volume of 42,365,020. The stock has a market cap of $163.65 billion, a price-to-earnings ratio of -481.25, a PEG ratio of 1.16 and a beta of 0.63. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $40.37. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The firm’s 50 day simple moving average is $27.27 and its two-hundred day simple moving average is $27.96.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business’s revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the business posted $1.23 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.82%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s payout ratio is currently -2,799.53%.

Analysts Set New Price Targets

PFE has been the subject of a number of recent research reports. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Finally, Morgan Stanley raised their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Ten analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.